Prot #17000139BLC3004: SunRISe-5: A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and

Project: Research project

Project Details

StatusActive
Effective start/end date7/16/2410/11/31

Funding

  • Janssen Research & Development, LLC (Prot #17000139BLC3004)